

Akebia Therapeutics, Inc.  
Form 8-K  
June 21, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported)**

**June 16, 2015**

**AKEBIA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-36352**  
**(Commission**  
  
**File Number)**

**20-8756903**  
**(I.R.S. Employer**  
  
**Identification No.)**

Edgar Filing: Akebia Therapeutics, Inc. - Form 8-K  
**245 First Street, Suite 1100, Cambridge, Massachusetts 02142**  
**(Address of Principal Executive Offices, including Zip Code)**  
**(617) 871-2098**  
**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 5.07 Submission of Matters to a Vote of Security Holders

Akebia Therapeutics, Inc. (the Company) held its 2016 Annual Meeting of Stockholders on June 16, 2016. The stockholders (i) elected two directors to the Board of Directors (the Board) to serve for three-year terms expiring in 2019; and (ii) ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2016. There were 37,765,632 outstanding shares eligible to vote as of April 18, 2016, the record date for the 2016 Annual Meeting.

The directors elected to the Board for terms expiring at the Annual Meeting in 2019, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below:

Director	Votes For	Votes Withheld	Broker Non-Votes
Anupam Dalal	21,987,210	3,517,208	7,456,735
Maxine Gowen	21,973,256	3,351,162	7,456,735

The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2016 received the following votes:

Votes For:	32,887,798
Votes Against:	61,878
Abstentions:	11,477

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AKEBIA THERAPEUTICS, INC.**

By: /s/ John P. Butler  
John P. Butler

President and Chief Executive Officer

Date: June 21, 2016